Zinc Acexamate

Developed for: hepatocellular carcinoma
Investigated by: Complejo Hospitalario de Toledo · Germans Trias i Pujol Hospital · Hospital Clinic of Barcelona · Hospital General Universitario Gregorio Marañon · Hospital Miguel Servet · Hospital Universitari Vall d'Hebron Research Institute
+9 more
· Hospital Universitari de Bellvitge · Hospital Universitario Central de Asturias · Hospital Universitario Marqués de Valdecilla · Hospital Vall d'Hebron · Hospital de la Santa creu i Sant Pau - Barcelona · Hospital del Mar · Parc Taulí Hospital Universitari · Puerta de Hierro University Hospital · University Hospital of Girona Dr. Josep Trueta

today NCT06434753 · Ph 3

2023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT06434753	Oct 2022 → Mar 2026	hepatocellular carcinoma, portal hypertension	Hospital Universitari Vall d'Hebron Research Institute	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Zinc Acexamate	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06434753 ↗
Known as	.epsilon.-acetamidocaproic acid zinc salt	ChEMBL registry synonym — accepted as the source's own label CHEMBL2105922 ↗
Known as	Acexamate zinc	ChEMBL registry synonym — accepted as the source's own label CHEMBL2105922 ↗
Known as	Acide acexamique	ChEMBL registry synonym — accepted as the source's own label CHEMBL2105922 ↗
Known as	Acido acexamico	ChEMBL registry synonym — accepted as the source's own label CHEMBL2105922 ↗
Known as	Copinal	ChEMBL registry synonym — accepted as the source's own label CHEMBL2105922 ↗
Known as	Zinc n-(acetylamino)-6-hexanoate	ChEMBL registry synonym — accepted as the source's own label CHEMBL2105922 ↗
Modality	Small molecule	— CHEMBL2105922 ↗